GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
N

Nexien Biopharma NXEN · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.00

0.00%

Close of 2 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2024

Net income

−$239,000

FY2015FY2024

Free cash flow

−$64,368

FY2015FY2024

Shareholders' equity

−$361,249

FY2015FY2024

Income statement

Fiscal years

FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015
Research and development————$15,169$63,858$116,791$73,457——
Operating income−$156,000−$283,000−$563,992−$1.8m−$2.6m−$3.9m−$1.3m−$258,653−$16,350−$46,675
Net income−$239,000−$362,000−$626,357−$1.9m−$2.7m−$4.3m−$1.3m−$258,653−$20,988−$48,440
Diluted earnings per share-0.00-0.01-0.01-0.03-0.05-0.08-0.02-0.01-0.00-0.00

Balance sheet

At each fiscal year end

FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015
Total assets$4,183$43,127$124,518$25,541$22,786$310,670$1.3m$773,692——
Cash and short-term investments$4,183$35,147$116,898$18,041$10,786$146,356$819,739$242,778——
Total liabilities$365,432$295,134$242,123$39,316$29,151$44,750$88,785$210,405$69,903$48,915
Debt$312,254$271,491$221,728$12,941$12,000—————
Shareholders' equity−$361,249−$252,007−$117,605−$13,775−$6,365$265,920$1.2m$563,287−$69,903−$48,915
Shares outstanding71m65m62m56m56m54m52m44m23m23m

Cash flow

Fiscal years

FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015
Cash from operations−$64,364−$81,751−$75,143−$90,745−$147,570−$643,383−$875,342−$129,532−$16,352−$46,730
Capital spending−$4—−$3−$5—−$30,000−$35,000−$65,000——
Free cash flow−$64,368−$81,751−$75,146−$90,750−$147,570−$673,383−$910,342−$194,532−$16,352−$46,730

Latest quarters

By quarter end

Mar 2025Dec 2024Sept 2024Jun 2024Mar 2024Dec 2023Sept 2023Jun 2023
Operating income−$14,300−$24,027−$15,710−$64,285−$15,947−$13,436−$61,995−$65,886
Net income−$30,092−$39,472−$32,004−$86,514−$53,163−$24,518−$74,918−$93,583
Diluted earnings per share-0.00-0.00-0.00-0.00-0.00-0.00-0.00-0.00
Total assets$8,285$1.31bn$4.95bn$4,183$14,267$2,619$22,054$43,127
Cash and short-term investments$8,285$1.31bn$4.95bn—$10,067$2,619$18,064$35,147
Debt$375,375$351,012$328,298—$295,032$280,454$231,893$271,491
Shareholders' equity−$450,516−$422.69bn−$391.75bn−$361,249−$325,291−$314,193−$290,800−$252,007

Growth per year

Compound annual rate

3 years5 years10 years
Operating income-56.1%-47.6%77.4%
Net income-49.5%-43.9%84.0%

Share price return

Finished calendar years

2025202420232022202120202019201820172016
Return1358%13543%89435%-8%-26%4165%98%-93%247002%19156426%

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 6-to-1 reverse split · 29 Nov 2017

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.